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Summary
 
Complement component 3 (C3), a critical regulator of innate immunity, may also play a role in
the regulation of cognate immunity, such as contact sensitivity responses. Because ultraviolet
(UV) radiation also activates C3 in the skin, we determined whether the immunosuppressed
state that results when a contact sensitizer is applied through UVB-exposed skin requires the
presence and activation of C3. This question was addressed through the use of C3-deficient
mice, blockade of C3 cleavage to C3b, and accelerated degradation of iC3b by soluble comple-
ment receptor 1 (sCR1). Both C3-modulated systems totally reversed the failure to induce a
contact sensitivity response to dinitrofluorobenzene (DNFB) upon primary sensitization at the
UV-exposed site, as well as immunologic tolerance to a second DNFB immunization through
normal skin. Treatment with sCR1 reduced the infiltration of CD11b
 
1
 
 leukocytes into the
epidermis and dermis of UV-irradiated skin but did not reverse the UV-induced depletion of
epidermal class II MHC
 
1
 
CD11b
 
lo
 
 Langerhans cells. These data, taken together with previous
results showing abrogation of locally induced UV immunosuppression by in vivo anti-CD11b
treatment, suggest a novel mechanism by which ligation of the leukocyte 
 
b
 
2 integrin, CD11b,
by iC3b molecules formed from C3 activation in UV-exposed skin, modifies cutaneous
CD11b
 
1
 
 cells such that skin antigen-presenting cells are unable to sensitize in a primary im-
mune response, but actively induce antigenic tolerance.
 
C
 
omplement components, especially complement com-
ponent 3 (C3), have been implicated in the regulation
of T cell–mediated responses (1, 2). More specifically, C3
(3), C4 (3, 4), and C5 (5) may be involved in modulating
the contact sensitivity response. In addition, C3 fragments
have been proposed as an inhibiting factor in the induction
of contact sensitivity (3). Thus, C3 activation may also be
involved in the UV-induction of an immunosuppressed state
to a contact sensitizer that has been applied to UV-irradi-
ated skin. C3, factor B, and the decay-accelerating factor
have all been demonstrated to be present in the epidermis
of normal skin (6). Cultured keratinocytes have also been
demonstrated to be able to produce C3 (7) as well as factor
B (8). In addition, the in vitro production of C3 by human
keratinocytes is upregulated by the proinflammatory cyto-
kine, TNF-
 
a
 
 (9). UVB radiation may be capable of activat-
ing the C3 produced by keratinocytes by the alternative
pathway (10). Complement activation has also been impli-
cated in UVB-induced local inflammation without affect-
ing the systemic complement system (11). Furthermore,
the receptor for the C3 fragment iC3b, CD11b, has re-
cently been demonstrated by in vivo antibody neutraliza-
tion experiments to be involved in UV-induced immu-
nosuppression (12), as well as in tissue injury. The cells
expressing CD11b in UV-exposed epidermis and that have
been shown to be critical for inducing immune tolerance
are an infiltrating population of monocyte–macrophage
cells.
Therefore, we hypothesize that C3 activation is critically
required for UV-induction of immunosuppression to a
contact sensitizer that is applied to skin exposed to a single
UV dose that generates locally inducible immunosuppres-
sion. This hypothesis was tested using mice with either a ge-
netic disruption of the C3 gene (C3-deficient mice; reference
13) or of the soluble complement receptor 1 (sCR1) block-
ing of C3b, and C3b formation/activation (14). Both models
conclusively demonstrate that C3 and its activation is re-
quired for induction of tolerance in our UVB mouse model.
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Materials and Methods
 
Mice.
 
C3H/HeN females were purchased from Charles
River (Wilmington, MA). (129 
 
3
 
 C57BL/6)F1 females were
purchased from the Jackson Laboratory (Bar Harbor, ME). C3-
deficient females were bred at the Harvard Medical School (Bos-
ton, MA). All mice were between the ages of 6 and 12 weeks of
age. Groups of four mice were used for each panel of the contact
sensitivity experiments.
 
Antibodies and Reagents.
 
2,4-dinitro-1-fluorobenzene (DNFB)
was purchased from Sigma Chemical Co. (St. Louis, MO). Solu-
ble CR1 was a gift from T Cell Sciences, Inc. (Needham, MA).
Ethidium monoazide and Cascade blue–conjugated avidin were
obtained from Molecular Probes (Eugene, OR). PE-conjugated
rat anti-CD11b (rat IgG2b, clone M1/70) was purchased from
Boehringer Mannheim (Indianapolis, IN). Biotin-conjugated
mouse anti-Ia
 
k
 
 (mouse IgG2b, clone 11-5.2) and FITC-conju-
gated rat anti–mouse Gr-1 (rat IgG2b, clone R86-8C5) were ob-
tained from PharMingen (San Diego, CA).
 
UV Induction of Tolerance.
 
Razor-shaved and chemically de-
pilated mouse skin was exposed as previously described (15) to
UVB irradiation from a band of six FS-40 fluorescent lamps from
which UVC and UVB wavelengths not present in natural solar
radiation have been filtered by Kodacel cellulose film (Eastman
Kodak Co., Rochester, NY) (16). A single UV exposure was ad-
ministered to each strain at a dose such that tolerance was induced
only if DNFB was applied to the UV-exposed skin and not a
non–UV-exposed distant site (low-dose, locally inducible toler-
ance). The UVB emission was measured with an IL-443 photo-
therapy radiometer (International Light, Newburyport, MA)
equipped with an IL SED 240 detector fitted with a W side angle
quartz diffuser and a SC5 280 filter. 48 h after UV exposure, mice
were sensitized with DNFB by administering 25 ml of 0.5%
DNFB in acetone/olive oil (4:1) onto the UV-exposed skin. 5 d
later, the dorsal surface of the ear was challenged with 20 ml of
0.2% DNFB in acetone/olive oil (4:1). 24 h later, ear thickness
was measured using an engineer’s micrometer (Mitutoyo, Tokyo,
Japan) and compared with ear thickness just before the challenge.
Tolerance was determined by resensitizing mice on razor-shaved
non–UV-exposed skin with DNFB 48 h after the primary chal-
lenge. 5 d after the secondary sensitization, mice were rechal-
lenged with DNFB on the dorsal skin of the left ear. Ear swelling
was measured immediately before and 24 h after secondary chal-
lenge. In these experiments four animals were used in each group.
Microosmotic pumps (Alzet model 1007D; Alza Corp., Palo
Alto, CA) containing sCR1 or PBS were inserted into the perito-
neal cavity of C3H/HeN mice 3 d before irradiation with a single
UVB dose of 72 mJ/cm
 
2
 
. C3-deficient mice and their (129 
 
3
 
C57Bl/6)F1 controls received a single UVB dose of 140 mJ/cm
 
2
 
.
Contact sensitizer was applied and tolerance was determined as
outlined above.
 
Flow Cytometric Analysis.
 
Epidermal cell suspensions were pre-
pared in 0.25% trypsin as previously described (12). In preparation
of epidermal cell suspensions 6–8 mice were used in each group
of the experiment.
As previously described (15), 10
 
6
 
 FcIgG receptor–blocked
(anti-CD16/32, clone 2.4G2; PharMingen) epidermal cells or
dermal cells obtained from skin 48 h after UV exposure were in-
cubated with the following set of mAbs: sCR1-treated C3H/
HeN mice; FITC-conjugated anti-Gr-1; PE-conjugated anti-
CD11b; and biotin-conjugated anti-Ia
 
k
 
. After washing, cells were
incubated with Cascade blue–conjugated avidin. Control tubes
were stained with matched conjugated isotype control immuno-
globulins. Dead cells were identified by uptake of ethidium
monoazide (15). Stained cells were fixed in 1% paraformaldehyde
before flow cytometric analysis by an Epics Elite Cytometer
(Coulter Electronics, Hialeah, FL). Positive cell percentages were
determined by calculating the percentage of the positive cell pop-
ulation in terms of total viable epidermal or dermal cells and sub-
tracting the percentage of cells found within the same positive
gate in the isotype control–stained samples.
 
Results
 
Absence of C3 Prevents UV Induction of Tolerance to a Con-
tact Sensitizer.
 
Mice deficient in C3 due to the disruption
of the C3 gene, which resulted in a mouse strain with un-
detectable levels of serum C3 (13), were assayed for the ef-
fect of UV upon contact sensitivity induction in a C3-defi-
cient environment. As done previously (17), a single UVB
dose was determined (data not shown) that induced toler-
ance only when the DNFB was applied 48 h after UV irra-
diation to the UV-exposed skin (locally induced tolerance)
and not at a distant non–UV-exposed site (systemically in-
duced tolerance). Based upon these criteria, a single UVB
dose of 140 mJ/cm
 
2
 
 for the C3-deficient mice and their
(129 
 
3
 
 C57BL/6)F1 controls was used. The absence of C3
did not affect the ability of C3-deficient mice to mount a
contact sensitivity response to DNFB (Fig. 1, bar 
 
2
 
 from
the top) that was comparable to that observed in (129 
 
3
 
C57BL/6)F1 controls (Fig. 1, bar 
 
5
 
). By contrast, C3-defi-
cient mice differed markedly from their (129 
 
3 
 
C57BL/
6)F1 controls; absence of C3 conferred protection from
UV’s ability to inhibit contact sensitization (Fig. 1, 
 
left
 
, bar
6 [UV inhibition] versus 5 [no UV sensitization in C3 suf-
ficient controls], as compared to no reduction in sensitiza-
tion after UV in C3-deficient mice [bar 
 
3
 
 versus 
 
2
 
]). Similarly,
C3-deficient mice were protected against the development
of tolerance to DNFB; UV-exposed C3-deficient mice
were not blocked in their ability to be resensitized through
normal skin (Fig. 1, 
 
right
 
, bars 
 
2
 
 and 
 
3
 
), as were normal
Figure 1. Failure of a single low UVB dose (140 mJ/cm2) to induce an
immunosuppressed state to a contact sensitizer applied through the UV-
irradiated skin of C3-deficient mice. The contact sensitivity responses of
C3-deficient mice (2/2) and their 1/1 controls (129 3 C57BL/6)F1 to
DNFB in the absence of UV exposure are shown in the second and fifth
bars from the top, respectively. The effect of a single UVB dose given 48 h
before application of DNFB to the UV-exposed site on the response to
DNFB by C3-deficient mice and their controls is given in the third and
sixth bars from the top, respectively. The left panel shows the ear swelling
response to primary sensitization through dorsal skin and challenge. The
right panel indicates the response to a second sensitization through normal
back skin and rechallenge. Data are expressed as the mean 6 SEM differ-
ence in ear thickness between pre- and postchallenge measurements. Four
mice were used in each group. 
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mice (Fig. 1, 
 
right
 
, bars 
 
5
 
 and 
 
6
 
). Thus, although C3 is not
needed for positive immune response development in this
model, C3 does appear to be critical for UV-induced
downregulatory responses.
 
C3 Activation Required for UV Induction of Immunosuppres-
sion.
 
We next determined whether C3 activation was re-
quired for the locally induced effects of UV upon suppres-
sion of contact sensitivity responses. C3 activation can be
blocked in vivo by sCR1, which both inactivates C3 con-
vertase (and C5 convertase) and accelerates degradation of
iC3b (14, 18) and in the mouse inhibits the alternative
pathway of C3 activation (19). Relative to non-sCR1–
treated C3H/HeN mice (Fig. 2, bar 
 
2
 
 from top), sCR1
treatment did not affect the contact sensitivity response to
DNFB after either the primary or secondary challenge (Fig.
2, bar 
 
3
 
). We have previously demonstrated that for C3H/
HeN, 72 mJ/cm
 
2
 
 is sufficient to create the local skin milieu
that can induce tolerance, but is not high enough to also
generate systemically acting factors that can induce toler-
ance even upon immunization through normal skin (17).
UV irradiation with 72 mJ/cm
 
2
 
 did inhibit both the primary
and secondary contact sensitivity response in non-sCR1–
treated mice (Fig. 2, bar 
 
4
 
). However, sCR1 treatment of
UV-exposed C3H/HeN mice completely prevented UV
injury of the skin’s ability to induce a primary contact sen-
sitivity response (Fig. 2, 
 
left
 
, bar 
 
5
 
). Furthermore, sCR1
fully reversed UV induction of tolerance (active suppres-
sion of ability to sensitize) (Fig. 2, 
 
right
 
, bar 
 
5
 
).
 
Effect of sCR1 Treatment on UV Modulation of Skin Leuko-
cyte Populations.
 
We have previously observed that treat-
ing mice with blocking antibodies to CD11b, the receptor
for iC3b, blocked CD11b
 
1
 
 leukocyte infiltration into both
the dermis and epidermis of UV-exposed skin (12). Since
sCR1 treatments block the UV-induced formation or sta-
ble accumulation of the CD11b ligand iC3b (data not
shown), it was determined whether sCR1 treatment also
affects leukocyte movement into UV exposed skin. Be-
cause skin-infiltrating leukocytes express both CD11b and
Gr-1 (17), and the tolerogenic cells in UV-exposed epider-
mis express CD11b, class II MHC (20), and GR-1 (not
shown), these markers were used to quantitate by flow cy-
tometry the effect of sCR1 treatment on UV-induced leu-
kocyte infiltration. The degree of UV-induced infiltrating
CD11b
 
1
 
Gr-1
 
1
 
 leukocytes was decreased in sCR1-treated
C3H/HeN in both epidermal (Fig. 3, 
 
A
 
 and 
 
B
 
, quadrant 
 
2
 
)
and dermal experiments (data not shown). Changes in the
other two cell populations, CD11b
 
1
 
Gr-1
 
2
 
 and CD11b
 
2
 
Gr-1
 
1
 
 in sCR1-treated UV-exposed mice did not consis-
tently increase or decrease. Essentially identical results were
obtained in a duplicate experiment.
Four-color flow cytometry was performed to determine
whether restoration of class II MHC
 
1
 
 antigen-presenting
cells is occurring in the UV-irradiated epidermis as a result
of sCR1 treatment (Fig. 3, 
 
C
 
 and 
 
D
 
). Class II MHC
 
1
 
 epi-
dermal Langerhans cells (LC) can be distinguished by their
low expression of CD11b compared to a high expression of
Figure 2. Reversal by sCR1 of induction of tolerance to a contact sen-
sitizer immunized through skin of C3H/HeN mice exposed to a single
UVB dose (72 mJ/cm2). The contact sensitivity response to DNFB of
mice receiving no UV with and without sCR1 treatment is given in the
third and second bars from the top, respectively. The response of mice re-
ceiving UV with no sCR1 is shown in the fourth bar from the top, and
with sCR1 in the fifth bar from the top. The left panel shows the ear
swelling response to primary sensitization through dorsal skin and chal-
lenge. The right panel indicates the response to secondary sensitization
through normal back skin and rechallenge. Data are expressed as de-
scribed in Fig. 1. Four mice were used in each group.
Figure 3. sCR1 treatment of UV-irradiated C3H/HeN mice partially
blocks infiltration of CD11b1 leukocytes but does not prevent UV-induced
depletion of class II MHC1CD11bloGr-12 LC. Three-color flow cyto-
metric analysis was used to determine the expression of CD11b and Gr-1
by epidermal cells obtained from the skin of C3H/HeN mice (A and B),
48 h after UV exposure, that had been treated with either PBS (A) or sCR1
(B). Cells were first selected based upon their viability (EMA exclusion),
then analyzed for CD11b expression (x-axis represents PE intensity) and
Gr-1 expression (y-axis represents FITC intensity). Cells stained with the
matching antibody isotype were confined to quadrant 3. Percentage of
stained cells after subtracting the isotype background are given for each
quadrant. Four-color flow cytometric analysis was used to identify class II
MHC1CD11bloGr-12 LC from UV-exposed epidermis of C3H/HeN
mice with (D) or without (C) sCR1 treatment. Determination of the ex-
pression of CD11b (y-axis represents PE intensity) and Gr-1 (x-axis rep-
resents FITC intensity) on class II MHC1 epidermal cells electronically
selected by their reactivity to biotin-conjugated anti-Iak and avidin-Cas-
cade blue was determined by flow cytometric analysis. For the preparation of
epidermal cell suspensions six to eight mice were used in each group. 
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CD11b by monocytes/macrophages (17). Normal levels of
class II MHC
 
1
 
CD11b
 
lo
 
 LC are 
 
z
 
4% (17); as a result of UV
irradiation, this population drops to 0.2% in C3H/HeN
(Fig. 3 
 
C
 
) mice. However, sCR1 pretreatment of UV-irra-
diated C3H/HeN mice did not affect the UV-induced
class II MHC
 
1
 
CD11b
 
lo
 
 LC depletion (Fig. 3 
 
D
 
, no restora-
tion of LC in quadrant 
 
F
 
). Shown is the experiment that
resulted in the median value from three separate experi-
ments of six to eight mice in each group. Similar results
were observed by staining for LC with anti–class II MHC
antibodies in tissue sections of skin from UV-irradiated and
sCR1-pretreated plus UV-irradiated C3H/HeN mice (data
not shown).
 
Discussion
 
Using two different in vivo mouse model systems in
which either C3 is deficient (C3 gene disruption) or C3 is
present and activation of C3 is inhibited (sCR1), it was
demonstrated that C3 is essential for UV induction of an
immunosuppressed state to a contact sensitizer. The UV
dose used for each mouse system was such that only when
the contact sensitizer was applied to the UV-irradiated skin,
and not at a distant site, was tolerance induced. Using such
UV doses in both C3 mouse models, reversal of UV induc-
tion of an immunosuppressed state was complete, indicat-
ing not only that C3 is required but that activation of C3
(sCR1 model) is essential. Treatment of normal mice with
sCR1 did not alter their ability to generate a contact sensi-
tivity response, indicating that sCR1 is not affecting the nor-
mal antigen-presenting cell–T cell interaction that results in
contact sensitivity. Because the UV dose used was local in
its effect on contact sensitization induction, this would im-
ply that the influence of UV-induced C3 activation upon
the generation of a contact sensitization response is also re-
stricted to the skin at the site of UV irradiation.
The complement components required for the activation
of C3 by the alternative pathway are all present in the skin.
C3 and its activating protease, factor B, have both been de-
tected in normal epidermis (6). In addition, production of
C3 and factor B by cultured keratinocytes has been dem-
onstrated (6–8). Cleavage fragments of C3 have also been
observed in the normal epidermal basement membrane
zone (21, 22). Moreover, complement deposits of C3b and
C3d have been detected in and on epidermal cells within
24 h of exposure of the skin to UVB, indicating activation
of C3 by UVB (10). Treatment with sCR1 eliminated the
presence of C3 deposits (data not shown), indicating that
the activation of C3 in the skin by UV was blocked by
sCR1 (inhibiting C3 cleavage to C3b).
sCR1 treatment of UV-irradiated C3H/HeN mice re-
sulted in a decreased, but not total inhibition of, leukocyte
infiltration into the UV-irradiated skin and little restoration
of class II MHC
 
1
 
 cells. Specifically, a recovery of class II
MHC
 
1
 
CD11b
 
lo
 
 LC was not observed in sCR1-treated,
UV-exposed C3H/HeN mice where sCR1 treatment also
restored a primary contact sensitivity response as well as
blocked tolerance induction. The lack of retention of LC
after UV when C3 degradation is blocked indicates the ef-
fect is not due to iC3b triggering of tolerogenic UV–LC
emigration. This finding implicates the involvement of
products of UV-induced C3 activation in the stimulation
of the development of a tolerance-inducing antigen-pre-
senting cell. C3a, a product of the initial cleavage of C3, is
capable of activating leukocytes as measured by increased
reactive oxygen species production (23). More direct evi-
dence for the involvement of C3 fragments in modifying
the development of antigen-presenting cells derives from
findings that C3b, the second fragment resulting from the
initial cleavage of C3, cross-links the C3b receptor (CD46),
resulting in inhibition of induction of IL-12 production
(24). IL-12 is critical for the successful induction of contact
sensitivity and reverses UV-induced immune suppression
(25–28). We have found that a deficiency of IL-12–pro-
ducing cells within the draining lymph nodes of UV-exposed,
contact-sensitized mice is associated with the induction of
tolerance in these animals (29).
However, C3b is highly unstable and rapidly undergoes
further cleavage by factor I, in the presence of factor H, re-
sulting in the generation of the more stable product, iC3b,
that binds to its receptor, CR3 (CD11b/CD18). Stimula-
tion of leukocytes through CD11b/CD18 by iC3b results
in activation of leukocytes (30). Cross-linking of CD11b
integrin on leukocytes results in increased tyrosine phos-
phorylation (31, 32), changes in intracellular calcium levels
(33–35), and increased reactive oxygen species production
(33, 34, 36). Thus, C3 fragments generated in UV-irradi-
ated skin may, through binding to their receptors, be pro-
viding a critical signal necessary for the development of an
antigen-presenting cell capable of inducing T suppressor
cells. Our previous data demonstrating complete blockade
of UV-induced tolerance by in vivo anti-CD11b treatment
and only partial blockade of CD11b
 
1
 
 leukocyte infiltration
(12) suggests the additional involvement of the CD11b
molecule (iC3b receptor) in tolerance induction. This hy-
pothesis is supported by recent publications that demon-
strate cross-linking the CD11b/CD18 molecule downreg-
ulates induction of interleukin-12 by monocytes (37, 38).
Furthermore, we have recently found that iC3b is capable
of inducing IL-10 in human monocytes (39).
Therefore, in our model both infiltrating and indigenous
CD11b-expressing antigen-presenting cells would be trig-
gered by UV-activated C3 into a state of differentiation/
activation that is insufficient to support initiation of a pri-
mary immune response, but in fact induces antigenic toler-
ance. However, in the absence of the iC3b/CD11b signal-
ing the infiltrating and indigenous (at least those remaining
after UV) antigen-presenting cells would acquire function-
alities (IL-12, costimulatory molecules) that support initia-
tion of a primary immune response. These results implicate
a novel mechanism of immunoregulation that can be oper-
ative or manipulated in UV injury, UV tumor immunity,
photosensitivity, and other cutaneous immune-mediated
diseases. 
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